- I am on the eve of departing for Osaka, Japan, for the Bio Japan 2006
conference as part of a small Illinois mission. I have written a number of times over the years about both the Japanese pharma and biotech industries, but I haven't been back to Japan for a few years and I'm looking forward to getting up to speed on t......Full article >>>
forward aggressively to implement common drug development parameters existing in countries such as the U.S. and Europe; in September 2003, they put into place Good Clinical Practice (GCP) standards. This measure alone has significant impact on the performance of clinical trials in China in a manner consistent with world-class standards.
The impact of GCP means not only the potential usabi......Full article >>>
According to a Sept. 1 article of Genetic Engineering News
on "Chinese Biogenerics," 95 percent of Chinese pharmaceutical products are generic. As patents now are being implemented, however, the growth of the proprietary and innovative drugs is growing rapidly.
Before the 1990s, Chinese pharmaceutical companies were unable t......Full article >>>
up its deficiencies in patent law beginning with the September 2002 "Regulations for Implementation of the Drug Administration Law," which modified the definition of a new drug to that of a drug that never been marketed or sold previously in China) Furthermore, China's patent law was amended on December 12, 2002 to harmonize China's patent system with other WTO countries.
China will have ......Full article >>>
Hangzhou Jiuyuan Gene Engineering.
Hualan Biological Engineering.
NCPC Genetech Biotechnology.
Source: "Chinese Biogenerics," Genetic Engineering News
, Sept. 1, 2006.
Chinese biogeneric companies have focused their efforts to date on such drugs as interferon, interleukins, GM-CMF, Erythropoetin (EPO), Hepatitis B vaccine, and re......Full article >>>
t shines among best hospitals in U.S.
Michael Rosen: The world of in-vitro diagnostics is another Midwest success story